GlassScriptPhysician profile
Walter A Klein
NPI 1821099078
$8,094.65
in general payments reported to CMS, 2019-2025
65 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $722 · 2021: $876 · 2022: $1,355 · 2023: $1,242 · 2024: $762 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,909.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,554.71 | 2019-2025 | |
| Novo Nordisk INC | $646.27 | 2019-2025 | Wegovy, Ozempic |
| Janssen Biotech, INC. | $571.65 | 2022-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $529.87 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $393.97 | 2019-2025 | Entyvio, Eohilia, Trintellix |
| Amgen INC. | $349.15 | 2019-2025 | Evenity, Prolia, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.10 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $263.42 | 2019-2022 | |
| Celgene Corporation | $252.15 | 2021-2024 | Zeposia |
| Olympus America INC. | $250.23 | 2019-2025 | Hanarostent Esophagus Tts(Ccc) |
| Merck Sharp & Dohme LLC | $249.25 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Ironwood Pharmaceuticals, INC | $179.62 | 2019-2024 | Linzess |
| Corcept Therapeutics | $172.31 | 2024-2025 | Korlym |
| Lilly USA, LLC | $136.89 | 2019-2025 | Mounjaro, Zepbound, Omvoh |
| E.R. Squibb & Sons, L.L.C. | $122.09 | 2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.